Larimar Therapeutics logo
Larimar Therapeutics
LRMR | NASDAQ
Chart Builder DCF Calculator
$3.00
-$0.02 (-0.66%)
At close: Nov 16, 2026, 4:00 PM ET
$3.03
+$0.03 (+1.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Larimar Therapeutics Company Profile

Company profile explained

Company Profile

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.

Key Executives

Name Position
Carole S. Ben-Maimon CEO & Director
Michael Celano Secretary & Chief Financial Officer
Francis Michael Conway Vice President & Controller
Gopi Shankar Chief Development Officer
Jennifer Spokes Johansson Vice President of Legal & Compliance
John Berman Vice President of Finance & Administration
John Harlow Jr. President & COO
Russell G. Clayton Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 01, 2026 4 Filing
Oct 01, 2026 3 Filing
Sep 29, 2026 8-K Current Report
Aug 04, 2026 10-Q Quarterly Report
Aug 04, 2026 8-K Current Report
Jul 08, 2026 4 Filing
Jun 29, 2026 8-K Current Report
May 20, 2026 4 Filing
May 20, 2026 4 Filing
May 20, 2026 4 Filing
View All SEC Filings ➞
Larimar Therapeutics
Larimar Therapeutics logo
Country United States
IPO Date Jun 19, 2014
Industry Biotechnology
Sector Healthcare
Employees 71
CEO Carole S. Ben-Maimon

Contact Details

Three Bala Plaza East Bala Cynwyd, Pennsylvania 19004 United States

Stock Details

Ticker Symbol LRMR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001374690
CUSIP Number 517125100
ISIN Number US5171251003
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.